Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $23.00 at Royal Bank Of Canada

Posted by Brian Himes on Aug 1st, 2026

Contineum Therapeutics (NASDAQ:CTNM – Free Report) had its price target hoisted by Royal Bank Of Canada from $22.00 to $23.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also issued reports on CTNM. Morgan Stanley boosted their price target on Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Contineum Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $20.25.

Get Our Latest Stock Analysis on CTNM

Contineum Therapeutics Trading Down 1.7%

Shares of NASDAQ CTNM opened at $15.49 on Friday. Contineum Therapeutics has a 12-month low of $5.07 and a 12-month high of $16.91. The company has a market cap of $579.17 million, a PE ratio of -8.95 and a beta of 0.70. The stock has a 50 day simple moving average of $13.64 and a 200-day simple moving average of $13.62.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. Sell-side analysts forecast that Contineum Therapeutics will post -1.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Contineum Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CTNM. China Universal Asset Management Co. Ltd. bought a new position in Contineum Therapeutics during the 4th quarter valued at $43,000. Strs Ohio acquired a new position in shares of Contineum Therapeutics during the 1st quarter valued at $27,000. Royal Bank of Canada raised its stake in shares of Contineum Therapeutics by 73.5% in the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after buying an additional 2,454 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Contineum Therapeutics by 500.0% in the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock worth $85,000 after buying an additional 6,030 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Contineum Therapeutics in the second quarter valued at $43,000.

About Contineum Therapeutics

(Get Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.